ClinicalTrials.gg
CompletedNCT02004093Updated Dec 4, 2014Results posted

A Study to Evaluate the Effect of the Combination of Pertuzumab With Carboplatin-Based Standard Chemotherapy in Patients With Recurrent Ovarian Cancer

A Phase 2 interventional study of pertuzumab and paclitaxel in Ovarian Cancer, sponsored by Hoffmann-La Roche. Completed at 34 sites in 9 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-12-04.

Sponsored by Hoffmann-La Roche · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
149
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 35 studies in Ovarian Neoplasms by Hoffmann-La Roche — none open to participants now, 3 under way, none of them phase 3. Ovarian Neoplasms · Hoffmann-La Roche.

Enrollment
11th of 30
149 · median 100
Started
2005
with 2 others
Phase 2
12 of 35
none open now
Registered
23rd of 35
by date

Among the 35 studies in Ovarian Neoplasms by Hoffmann-La Roche, this one is the 11th largest by enrollment of the 30 interventional ones that give a count, is one of 3 that started in 2005, is one of 12 in phase 2, and was the 23rd registered.

Ovarian Neoplasms

3,387 studies on the registry are indexed under Ovarian Neoplasms; 792 are open to participants now.

Browse Ovarian Neoplasms studies →

Open to participants now

None of the 35 studies in Ovarian Neoplasms by Hoffmann-La Roche is open now. The open studies under Ovarian Neoplasms, anywhere →

Who these studies take

Of the 605 Ovarian Neoplasms studies recruiting now, 442 (73%) set no upper age limit and 107 (18%) stop at 75 or younger; 39 take children under 18; 45 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 35 studies in Ovarian Neoplasms by Hoffmann-La Roche as a file.
02

Study summary

This study will evaluate the efficacy and safety of pertuzumab in combination with carboplatin-based standard chemotherapy in patients with platinum-sensitive recurrent ovarian cancer. The anticipated time on study treatment is 3-12 months.

03

Conditions studied

  • Ovarian Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • confirmed ovarian, primary peritoneal, or fallopian tube cancer;
  • only 1 previous regimen, which must be platinum-based;
  • platinum-sensitive disease which is defined by a progression-free interval of greater than 6 months after completion of platinum-based chemotherapy.

Exclusion criteria

Exclusion Criteria:

  • previous radiotherapy;
  • previous treatment with an anti-cancer vaccine or any targeted therapy;
  • major surgery or traumatic injury within 4 weeks of study;
  • history or evidence of central nervous system .
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
149 participants (actual)

Study arms

  • Experimental
    Chemotherapy + Pertuzumab

    Drug: pertuzumab · Drug: paclitaxel · Drug: gemcitabine · Drug: carboplatin

  • Active comparator
    Chemotherapy

    Drug: paclitaxel · Drug: gemcitabine · Drug: carboplatin

Interventions

  • Loading dose of 840 mg IV, followed by 420 mg IV every 3 weeks

  • 175 mg/m2 IV every 3 weeks for 6 cycles

  • 1000 mg/m2 IV Day 1 and 8 of each cycle for 6 cycles

  • Target AUC of 5 following paclitaxel or AUC of 4 following gemcitabine IV every 3 weeks for 6 cycles

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Disease Progression or Death

    Disease progression was assessed according to RECIST (Response Evaluation Criteria In Solid Tumors), for participants with measurable disease, or by changes in CA 125 (Cancer Antigen 125) according to GCIG (Gynecologic Cancer Inter Group) for all participants. Participants who did not progress or died while being followed were censored at the time of the last valid tumor assessment or valid CA 125 assessment.

    Time frame: Screening and Day 15 of Cycles 2, 4, 6, and Day 15 of all cycles from Cycle 7 to 17 until disease progression up to 104 weeks

  2. Progression-Free Survival

    Progression-free survival was defined as the time from first administration of study drug (Study Day 1) to documented disease progression or death, whichever occurred earlier. Disease progression was assessed according to RECIST, for participants with measurable disease, or by changes in CA 125 according to GCIG for all participants. Participants who did not progress or died while being followed were censored at the time of the last valid tumor assessment or valid CA 125 assessment.

    Time frame: Screening and Day 15 of Cycles 2, 4, 6, and Day 15 of all cycles from Cycle 7 to 17 until disease progression up to 104 weeks

  3. Kaplan-Meier Probability of No Disease or Progression at 1 Year

    The probability of being event free (no disease progression or death events) at 1 year in participants remaining at risk.

    Time frame: 1 year

Secondary outcomes

  1. Percentage of Participants With a Best Overall Confirmed Response Based on Combined CA 125 and RECIST Measurements

    Response by tumor measurement occurred if there was documented and confirmed complete response (CR) or partial response (PR). For all participants, response was assessed by both the RECIST and by CA 125 levels, according to whether the participant had measurable or non-measurable disease at baseline. Response according to CA 125 levels was defined as at least a 50% reduction from baseline. The decrease had to be confirmed and maintained for at least 28 days. The confirmatory sample must have been less than or equal to the previous sample (within an assay variability of 10%). For overall response, the response categories were "response", "stable disease" and "progressive disease". Stable disease included 1) stable disease as defined by RECIST for solid tumors and 2) CA 125 levels that had not met the definition of "response" or "progressive disease".

    Time frame: Screening and Day 15 of Cycles 2, 4, 6, and Day 15 of all cycles from Cycle 7 to 17 until disease progression up to 104 weeks

  2. Duration of Response

    For participants who achieved a response, the duration of response was defined as the interval between initial documentation of response to the first documentation of disease progression or death. Participants who responded and did not progress or die while on study or while being followed were censored at the last valid tumor or CA 125 measurement.

    Time frame: Day 15 of Cycles 2, 4, 6, and Day 15 of all Cycles from Cycle 7 to 17 until disease progression up to 104 weeks

  3. Kaplan-Meier Probability of Maintaining a Response to at Least 1 Year

    Time frame: 1 year

  4. Percentage of Participants With Disease Progression

    Disease progression was assessed according to RECIST, for participants with measurable disease, or by changes in CA 125 according to GCIG for all participants. Participants who did not progress while being followed were censored at the time of the last valid tumor assessment or valid CA 125 assessment.

    Time frame: Screening and Day 15 of Cycles 2, 4, 6, and Day 15 of all cycles from Cycle 7 to 17 until disease progression

  5. Time to Progressive Disease

    The time to progressive disease is the interval of time from date of first dose of study medication to date of first documentation of progressive disease by either RECIST or CA 125 criteria. Participants who never progressed while being followed were censored at the last valid tumor measurement or CA 125 measurement.

    Time frame: Screening and Day 15 of Cycles 2, 4, 6, and Day 15 of all cycles from Cycle 7 to 17 until disease progression

  6. Kaplan-Meier Probability of Being Progression Free at 1 Year

    Time frame: 1 year

  7. Time To Response

    Time to response was the date of first dose of study medication to the date of the first documentation of response, according to CA 125 criteria for all participants or response according to RECIST criteria for participants with measurable disease. If response was evaluable by both criteria, then the date of response was for the earlier of the two events.

    Time frame: Screening and Day 15 of Cycles 2, 4, 6, and Day 15 of all cycles from Cycle 7 to 17 until 2 years after last dose of treatment

  8. Percentage of Participants Who Died

    Time frame: Screening and Day 15 of Cycles 2, 4, 6, and Day 15 of all cycles from Cycle 7 to 17 until 2 years after last dose of treatment

  9. Overall Survival

    Survival was the interval of time from date of first dose of study medication to date of death at any time. Participants who had not died were censored at the date of last contact when they were known to be alive.

    Time frame: Screening and Day 15 of Cycles 2, 4, 6, and Day 15 of all cycles from Cycle 7 to 17 until 2 years after last dose of treatment

  10. Kaplan-Meier Probability of Being Alive at 1 Year

    Time frame: 1 year

07

Results

Posted Dec 4, 2014

Participant flow

Participant flow — Overall Study
MilestoneChemotherapy + PertuzumabChemotherapy
Started7574
Completed11
Not completed7473
Withdrew: Death21
Withdrew: Lack of efficacy6662
Withdrew: Protocol violation01
Withdrew: Lost to follow-up01
Withdrew: Withdrawal by subject37
Withdrew: Other31

Outcome measures

PrimaryPercentage of Participants With Disease Progression or Death

Disease progression was assessed according to RECIST (Response Evaluation Criteria In Solid Tumors), for participants with measurable disease, or by changes in CA 125 (Cancer Antigen 125) according to GCIG (Gynecologic Cancer Inter Group) for all participants. Participants who did not progress or died while being followed were censored at the time of the last valid tumor assessment or valid CA 125 assessment.

Time frame:
Screening and Day 15 of Cycles 2, 4, 6, and Day 15 of all cycles from Cycle 7 to 17 until disease progression up to 104 weeks
Reported as:
Number · percentage of participants
Percentage of Participants With Disease Progression or Death
percentage of participantsChemotherapy + PertuzumabChemotherapy
Percentage of Participants With Disease Progression or Death87.880.0
PrimaryProgression-Free Survival

Progression-free survival was defined as the time from first administration of study drug (Study Day 1) to documented disease progression or death, whichever occurred earlier. Disease progression was assessed according to RECIST, for participants with measurable disease, or by changes in CA 125 according to GCIG for all participants. Participants who did not progress or died while being followed were censored at the time of the last valid tumor assessment or valid CA 125 assessment.

Time frame:
Screening and Day 15 of Cycles 2, 4, 6, and Day 15 of all cycles from Cycle 7 to 17 until disease progression up to 104 weeks
Reported as:
Median · weeks
Progression-Free Survival
weeksChemotherapy + PertuzumabChemotherapy
Progression-Free Survival34.1 (31 to 38)40.0 (33 to 43)
Statistical analysis
  • Chemotherapy + Pertuzumab vs Chemotherapy · Log Rank · p = 0.3967
  • Chemotherapy + Pertuzumab vs Chemotherapy · Wilcoxon (Mann-Whitney) · p = 0.4552
  • Chemotherapy + Pertuzumab vs Chemotherapy · Wald test · p = 0.3972 (p-value resulting from Wald test of null hypothesis that the hazard ratio equals (=) 1) · Hazard ratio (hr): 1.17 · 80% CI 0.92 to 1.49
SecondaryPercentage of Participants With a Best Overall Confirmed Response Based on Combined CA 125 and RECIST Measurements

Response by tumor measurement occurred if there was documented and confirmed complete response (CR) or partial response (PR). For all participants, response was assessed by both the RECIST and by CA 125 levels, according to whether the participant had measurable or non-measurable disease at baseline. Response according to CA 125 levels was defined as at least a 50% reduction from baseline. The decrease had to be confirmed and maintained for at least 28 days. The confirmatory sample must have been less than or equal to the previous sample (within an assay variability of 10%). For overall response, the response categories were "response", "stable disease" and "progressive disease". Stable disease included 1) stable disease as defined by RECIST for solid tumors and 2) CA 125 levels that had not met the definition of "response" or "progressive disease".

Time frame:
Screening and Day 15 of Cycles 2, 4, 6, and Day 15 of all cycles from Cycle 7 to 17 until disease progression up to 104 weeks
Reported as:
Number · percentage of participants
Percentage of Participants With a Best Overall Confirmed Response Based on Combined CA 125 and RECIST Measurements
percentage of participantsChemotherapy + PertuzumabChemotherapy
Percentage of Participants With a Best Overall Confirmed Response Based on Combined CA 125 and RECIST Measurements74.368.0
Statistical analysis
  • Chemotherapy + Pertuzumab vs Chemotherapy · Chi-squared · p = 0.3943 · Difference in response rates: 6.32 · 80% CI -3.9 to 16.6
  • Chemotherapy + Pertuzumab vs Chemotherapy · Odds ratio (or): 1.36 · 80% CI 0.86 to 2.17approximate 80% confidence interval (CI) for difference of two rates using Hauck-Anderson method
SecondaryDuration of Response

For participants who achieved a response, the duration of response was defined as the interval between initial documentation of response to the first documentation of disease progression or death. Participants who responded and did not progress or die while on study or while being followed were censored at the last valid tumor or CA 125 measurement.

Time frame:
Day 15 of Cycles 2, 4, 6, and Day 15 of all Cycles from Cycle 7 to 17 until disease progression up to 104 weeks
Reported as:
Median · weeks
Duration of Response
weeksChemotherapy + PertuzumabChemotherapy
Duration of Response28.7 (22 to 48)37.0 (25 to 43)
Statistical analysis
  • Chemotherapy + Pertuzumab vs Chemotherapy · Log Rank · p = 0.3655
  • Chemotherapy + Pertuzumab vs Chemotherapy · Wilcoxon (Mann-Whitney) · p = 0.1319
  • Chemotherapy + Pertuzumab vs Chemotherapy · Wald test · p = 0.3679 · Hazard ratio (hr): 1.22 · 80% CI 0.92 to 1.61p-value resulting from Wald test of null hypothesis that the hazard ratio=1
SecondaryKaplan-Meier Probability of Maintaining a Response to at Least 1 Year
Time frame:
1 year
Reported as:
Number · percent
Kaplan-Meier Probability of Maintaining a Response to at Least 1 Year
percentChemotherapy + PertuzumabChemotherapy
Kaplan-Meier Probability of Maintaining a Response to at Least 1 Year1818
SecondaryPercentage of Participants With Disease Progression

Disease progression was assessed according to RECIST, for participants with measurable disease, or by changes in CA 125 according to GCIG for all participants. Participants who did not progress while being followed were censored at the time of the last valid tumor assessment or valid CA 125 assessment.

Time frame:
Screening and Day 15 of Cycles 2, 4, 6, and Day 15 of all cycles from Cycle 7 to 17 until disease progression
Reported as:
Number · percentage of participants
Percentage of Participants With Disease Progression
percentage of participantsChemotherapy + PertuzumabChemotherapy
Percentage of Participants With Disease Progression83.876.0
SecondaryTime to Progressive Disease

The time to progressive disease is the interval of time from date of first dose of study medication to date of first documentation of progressive disease by either RECIST or CA 125 criteria. Participants who never progressed while being followed were censored at the last valid tumor measurement or CA 125 measurement.

Time frame:
Screening and Day 15 of Cycles 2, 4, 6, and Day 15 of all cycles from Cycle 7 to 17 until disease progression
Reported as:
Median · weeks
Time to Progressive Disease
weeksChemotherapy + PertuzumabChemotherapy
Time to Progressive Disease34.3 (27 to 48)37.3 (29 to 47)
Statistical analysis
  • Chemotherapy + Pertuzumab vs Chemotherapy · Log Rank · p = 0.8129
  • Chemotherapy + Pertuzumab vs Chemotherapy · Wilcoxon (Mann-Whitney) · p = 0.6920
  • Chemotherapy + Pertuzumab vs Chemotherapy · Wald test · p = 0.8137 · Hazard ratio (hr): 1.04 · 80% CI 0.82 to 1.32p-value resulting from Wald test of null hypothesis that the hazard ratio=1
SecondaryKaplan-Meier Probability of Being Progression Free at 1 Year
Time frame:
1 year
Reported as:
Number · percent
Kaplan-Meier Probability of Being Progression Free at 1 Year
percentChemotherapy + PertuzumabChemotherapy
Kaplan-Meier Probability of Being Progression Free at 1 Year2419
PrimaryKaplan-Meier Probability of No Disease or Progression at 1 Year

The probability of being event free (no disease progression or death events) at 1 year in participants remaining at risk.

Time frame:
1 year
Reported as:
Number · percent
Kaplan-Meier Probability of No Disease or Progression at 1 Year
percentChemotherapy + PertuzumabChemotherapy
Kaplan-Meier Probability of No Disease or Progression at 1 Year2421
SecondaryTime To Response

Time to response was the date of first dose of study medication to the date of the first documentation of response, according to CA 125 criteria for all participants or response according to RECIST criteria for participants with measurable disease. If response was evaluable by both criteria, then the date of response was for the earlier of the two events.

Time frame:
Screening and Day 15 of Cycles 2, 4, 6, and Day 15 of all cycles from Cycle 7 to 17 until 2 years after last dose of treatment
Reported as:
Median · weeks
Time To Response
weeksChemotherapy + PertuzumabChemotherapy
Time To Response6.0 (5 to 17)6.3 (5 to 15)
Statistical analysis
  • Chemotherapy + Pertuzumab vs Chemotherapy · Log Rank · p = 0.5726
  • Chemotherapy + Pertuzumab vs Chemotherapy · Wilcoxon (Mann-Whitney) · p = 0.3903
  • Chemotherapy + Pertuzumab vs Chemotherapy · Wald test · p = 0.5870 · Hazard ratio (hr): 1.11 · 80% CI 0.87 to 1.43p-value resulting from Wald test of null hypothesis that the hazard ratio=1
SecondaryPercentage of Participants Who Died
Time frame:
Screening and Day 15 of Cycles 2, 4, 6, and Day 15 of all cycles from Cycle 7 to 17 until 2 years after last dose of treatment
Reported as:
Number · percentage of participants
Percentage of Participants Who Died
percentage of participantsChemotherapy + PertuzumabChemotherapy
Percentage of Participants Who Died45.941.3
SecondaryOverall Survival

Survival was the interval of time from date of first dose of study medication to date of death at any time. Participants who had not died were censored at the date of last contact when they were known to be alive.

Time frame:
Screening and Day 15 of Cycles 2, 4, 6, and Day 15 of all cycles from Cycle 7 to 17 until 2 years after last dose of treatment
Reported as:
Median · months
Overall Survival
monthsChemotherapy + PertuzumabChemotherapy
Overall Survival28.2 (1 to 52)NA (1 to 34)
Statistical analysis
  • Chemotherapy + Pertuzumab vs Chemotherapy · Log Rank · p = 0.9261
  • Chemotherapy + Pertuzumab vs Chemotherapy · Wilcoxon (Mann-Whitney) · p = 0.8591
  • Chemotherapy + Pertuzumab vs Chemotherapy · Wald test · p = 0.9262 (p-value resulting from Wald test of null hypothesis that the hazard ratio=1) · Hazard ratio (hr): 1.02 · 80% CI 0.74 to 1.41
SecondaryKaplan-Meier Probability of Being Alive at 1 Year
Time frame:
1 year
Reported as:
Number · percent
Kaplan-Meier Probability of Being Alive at 1 Year
percentChemotherapy + PertuzumabChemotherapy
Kaplan-Meier Probability of Being Alive at 1 Year8885

Adverse events

Collected over Adverse events were collected from the date of randomization until 28 days after the last dose of the pertuzumab and/ or standard chemotherapy and continuously until end of study.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Chemotherapy + Pertuzumab—20/75 (26.7%)72/75 (96%)
Chemotherapy—12/74 (16.2%)68/74 (91.9%)
Most frequent serious events
Showing 10 of 30
Most frequent serious events
EventChemotherapy + PertuzumabChemotherapy
Drug hypersensitivityImmune system disorders4/750/74
Febrile neutropeniaBlood and lymphatic system disorders0/753/74
Abdominal painGastrointestinal disorders2/751/74
DiarrhoeaGastrointestinal disorders2/750/74
Intestinal obstructionGastrointestinal disorders2/750/74
VomitingGastrointestinal disorders2/750/74
PyrexiaGeneral disorders2/750/74
AscitesGastrointestinal disorders1/751/74
ConstipationGastrointestinal disorders0/751/74
Large intesting perforationGastrointestinal disorders0/751/74
Most frequent other events
Showing 10 of 54
Most frequent other events
EventChemotherapy + PertuzumabChemotherapy
NauseaGastrointestinal disorders44/7533/74
DiarrhoeaGastrointestinal disorders44/7514/74
NeutropeniaBlood and lymphatic system disorders36/7543/74
FatigueGeneral disorders30/7527/74
AlopeciaSkin and subcutaneous tissue disorders22/7525/74
VomitingGastrointestinal disorders24/7522/74
ConstipationGastrointestinal disorders20/7522/74
AnaemiaBlood and lymphatic system disorders19/7521/74
Decreased appetiteMetabolism and nutrition disorders19/754/74
ThrombocytopeniaBlood and lymphatic system disorders11/7518/74

Baseline characteristics

All participants who received randomized treatment (All Treated Population, for Efficacy Analyses); 1 participant was randomized to the chemotherapy arm but received pertuzumab+chemotherapy and is thus included in this arm for all analyses.

Age, Continuous
Age, Continuous(years)Chemotherapy + PertuzumabChemotherapyTotal
Mean58.1 ± 10.1655.3 ± 11.4156.7 ± 10.86
Sex: Female, Male
Sex: Female, Male(Participants)Chemotherapy + PertuzumabChemotherapyTotal
Female7475149
Male000
08

Study locations

34 sites
  • Bruxelles, 1000, Belgium
  • Leuven, 3000, Belgium
  • Wilrijk, 2610, Belgium
  • Calgary, Alberta T2N 4N2, Canada
  • Kelowna, British Columbia V1Y 5L3, Canada
  • Vancouver, British Columbia V5Z 4E6, Canada
  • Budapest, 1122, Hungary
  • Debrecen, 4032, Hungary
  • Gyor, 9024, Hungary
  • Parma, Emilia-Romagna 43100, Italy
  • Milano, Lombardia 20133, Italy
  • Amsterdam, 1066 CX, Netherlands
  • Amsterdam, 1081 HV, Netherlands
  • Poznan, 60-535, Poland
  • Warszawa, 02-781, Poland
  • Kazan, 420029, Russian Federation
  • Moscow, 105203, Russian Federation
  • Moscow, 115478, Russian Federation
  • Moscow, 117837, Russian Federation
  • Moscow, 125284, Russian Federation
  • Moscow, 143423, Russian Federation
  • Saint-Petersburg, 197022, Russian Federation
  • St Petersburg, 197758, Russian Federation
  • Tomsk, 634028, Russian Federation
  • Barcelona, 08035, Spain
  • Barcelona, 08036, Spain
  • Madrid, 28041, Spain
  • Valencia, 46009, Spain
  • Birmingham, B18 7QH, United Kingdom
  • London, W12 OHS, United Kingdom
  • Manchester, M20 4BX, United Kingdom
  • Plymouth, PL6 8DH, United Kingdom
  • Sutton, SM2 5PT, United Kingdom
  • Yeovil, BA21 4AT, United Kingdom
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2005, a primary completion of Sep 2008 and a completion of Sep 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Dec 2014, 6 years 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 3, 2013
First posted
Dec 6, 2013
Start
Dec 2005
Primary completionActual
Sep 2008
CompletionActual
Sep 2008
Results first posted
Dec 4, 2014
Last update
Dec 4, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 4, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02004093
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Dec 6, 2013
Start date
Dec 2005
Primary completion
Sep 2008
Completion
Sep 2008
Results posted
Dec 4, 2014
Last update
Dec 4, 2014

Study contacts

Clinical Trials
study chair · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pertuzumab

Start the discussion